#USA #New York #Securities Class Action #Faruqi & Faruqi #ImmunityBio

ImmunityBio Investors Alert: Class Action Deadline Approaching

Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities, is actively reminding investors of ImmunityBio, Inc. about an impending deadline for a federal securities class action. If you've purchased ImmunityBio shares between January 19, 2026, and March 24, 2026, you may be eligible to take part as a lead plaintiff in this lawsuit, which aims to hold the company accountable for alleged violations of securities laws.

Background

ImmunityBio has been under scrutiny following claims that its leadership made misleading statements regarding the company's therapeutic products, particularly concerning the drug Anktiva. Notably, concerns arose after the release of clinical trial results concerning the effectiveness of a chemotherapy-free immunotherapy regimen for glioblastoma patients. Reports indicated that the primary endpoint regarding median overall survival had not yet been met, resulting in a significant drop in ImmunityBio's stock price by over 12% immediately following the announcement.

Legal Framework

The class action lawsuit alleges that ImmunityBio and certain executives, including Patrick Soon-Shiong, exaggerated the capabilities of Anktiva, thus misleading investors about the company's operational outlook and potential benefits. Such actions may constitute violations of federal securities laws, which are designed to protect investors from misleading information in the financial markets.

Steps for Investors

Investors who have suffered financial losses due to these misleading statements are strongly encouraged to seek legal advice. According to James (Josh) Wilson, a partner at Faruqi & Faruqi, affected individuals should reach out to discuss their options. Investors can contact him directly at the firm’s offices to understand more about their legal rights and the possibility of joining the class action.

It's important to note that the deadline to apply as a lead plaintiff is May 26, 2026. The lead plaintiff represents the class and oversees the litigation, which could lead to potential recoveries if the lawsuit is successful.

How to Get Involved

If you believe you qualify for this class action, you can reach out to Faruqi & Faruqi for a free consultation. They invite individuals who have relevant information or have been impacted by ImmunityBio's conduct—including whistleblowers and former employees—to come forward.

You may also choose to opt-out of the lawsuit and remain an absent class member if you prefer not to take any action. However, your potential recovery will not be affected by this decision.

To learn more about the ongoing class action against ImmunityBio or to connect with the legal team, visit www.faruqilaw.com/IBRX or call 877-247-4292 to speak directly with a representative.

Final Thoughts

As investors navigate the complexities of investing in biotech and health sectors, remaining informed about possible legal recourse and options is crucial. As this situation develops, staying connected with reliable legal counsel and financial advisors can help protect your interests and investments moving forward.